Clinical Performance Evaluation of AMH Assay
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada
- Clinique ovo
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85258
- BRI
-
-
California
-
Palo Alto, California, United States, 94305
- Stanford
-
San Diego, California, United States, 92123
- FSMG
-
-
Delaware
-
Newark, Delaware, United States, 19713
- RAD
-
-
Florida
-
Clearwater, Florida, United States, 33759
- WRMG
-
-
Illinois
-
Swansea, Illinois, United States, 62226
- Vios Fertility
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- BIVF
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, United States, 19010
- Mainline Fertility
-
Philadelphia, Pennsylvania, United States, 19104
- Univ Pennsylvania
-
-
Texas
-
Dallas, Texas, United States, 76022
- CARE
-
Webster, Texas, United States, 77598
- CORM
-
-
Washington
-
Seattle, Washington, United States, 98104
- PNWF
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥ 21 and < 46 years of age
- Regular menstrual cycle
- Both ovaries present
Exclusion Criteria:
- Evidence of PCOS
- Confirmed ovarian endometrioma
- Ovarian surgery prior to enrollment
- Being treated for cancer
- Hormonal contraceptive use prior to enrollment
- Currently pregnant
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement of AMH as an aid for fertility assessment
Time Frame: Day 2 to 4 of menstrual cycle
|
Comparison of AMH levels in women at different levels of AFC to aid in assessing ovarian reserve
|
Day 2 to 4 of menstrual cycle
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Fred Siebert, Beckman Coulter
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- AMH 2.7.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anti-Mullerian Hormone
-
NCT01723085TerminatedAnti-Mullerian Hormone
-
NCT03826888CompletedAnti-Mullerian Hormone Isoforms
-
NCT03106272CompletedAnti-Mullerian Hormone Resistance
-
NCT00928044UnknownOvarian Reserve | Gynecologic Operations | Anti-Mullerian Hormone
-
NCT06999291Not yet recruitingAnti-Mullerian Hormone Deficiency
-
NCT03492632CompletedPsoriasis | Ovarian Reserve | Anti Mullerian Hormone
-
NCT04762615CompletedImmunosuppression | Ovarian Reserve | Anti-Mullerian Hormone Deficiency | X-rays; Effects
-
NCT03897400CompletedCrohn Disease | Anti-Mullerian Hormone Deficiency | Ovary Disease
-
NCT06263192CompletedInfertility, Female | Anti-Mullerian Hormone Deficiency
-
NCT03907605CompletedPost Partum Hemorrhage | Anti-Mullerian Hormone Deficiency
Clinical Trials on Access AMH Assay
-
NCT05969574RecruitingMiscarriage, Recurrent | Miscarriage | Infertility, Female | IVF
-
NCT04822857CompletedHypertension | Menopause
-
NCT07164924CompletedMultiple Sclerosis | Fertility | Neuromyelitis Optica Spectrum Disorders
-
NCT02739269Completed
-
NCT07278960RecruitingChildren | ART | Anthropometric Characteristics | Somatic Health Status | Neurological Condition | Urogenital Pathology
-
NCT07288762Not yet recruitingThalassemia Majors (Beta-Thalassemia Major)
-
NCT04762615CompletedImmunosuppression | Ovarian Reserve | Anti-Mullerian Hormone Deficiency | X-rays; Effects